News
Académie suisse des sciences techniques SATW
From foresight to first patients: HAYA Therapeutics enters the clinic
The Lausanne-based company HAYA Therapeutics, featured in the Technology Outlook showcase “The cryptic messages of our genome”, has reached two significant milestones in quick succession: the first cohort of participants has been dosed in a Phase 1 clinical trial of its lead candidate HTX-001, and the company has been named a “Disruptive Pioneer” in the 2026 Global Pharmaceutical Innovation and Invention Index published by IDEA Pharma. These developments underscore the relevance of the technology identified by SATW’s foresight activities.



